Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The rationale for the study is to obtain safety data as well as to establish dose parameters
for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as
photosensitizer for the treatment of recurrent prostate cancer.